Adjuvant Pembrolizumab, Durvalumab, and More Considerations From UC Trials Presented at ESMO 2024

By Guru P. Sonpavde, MD - Last Updated: September 26, 2024

Dr. Guru Sonpavde continues his discussion of urologic oncology trials presented at ESMO Congress 2024 by analyzing the efficacy of the SMARCA2 degrader, nivolumab plus gemcitabine and cisplatin, and neoadjuvant and adjuvant durvalumab.

Watch the first part of our interview with Dr. Sonpavde here.

BRAVO Study: Blue Light Cystoscopy Reduces Recurrence in Patients With NMIBC

Emily MenendezUrothelial Carcinoma Diagnostics | March 20, 2025

Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025

Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.

Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.

Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 21, 2025

The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.

Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.

Adjuvant Pembrolizumab, Durvalumab, and More Considerations From UC Trials Presented at ESMO 2024

Related Posts